Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD)

You likely can't join if

• - Presence of any of the following: Sinus or cerebral venous thrombosis, intracerebral hemorrhage, subarachnoid hemorrhage on qualifying imaging (cCT with CT-A or MRI with MR-A). However, petechial hemorrhagic transformation of index infarct and cerebral microhemorrhage may be included. - Active malignant tumor disease in the past 6 months. - Current known immunosuppression due to immunomodulatory medication with immunosuppressive dose or underlying immunosuppressive disease (e.g., HIV) - Acute fulminant infectious disease in the last 7 days (fever > 38.5°C or suspected by investigator) - Breastfeeding or pregnant woman, women of childbearing age (under 55 years) without known contraceptive use with positive urine or serum beta-human choriogonadotropin tests - Ischemic stroke or myocardial infarction in the previous 30 days - Surgery in the previous 30 days, except minor dermatologic, urologic, oral surgery, or gynecologic surgery without anesthesia and wound healing problems, and patients with thrombectomy - Estimated or known weight > 100 kg - Known allergies or intolerance to dornase alfa (Pulmozyme) or recombinant protein products derived from Chinese hamster ovary cells - Thrombocytopenia, leukocyte count <1500/μl - Known participation in another clinical trial investigating a drug and/ or medical device in the 7 days prior to study enrollment - Severe renal insufficiency with GFR≤29 ml/min/ 1.73m3 and/or renal insufficiency requiring dialysis